


Claims

What is claimed is:

1. A compound having Formula (III), or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof,




wherein X is -O-, -S-, -NH- or $^*-CR^9=CR^{9a}-$, wherein * refers to an end attached to the benzene ring; and


each R^1 , R^2 , R^3 , R^4 , R^9 and R^{9a} is independently H, D, $-CD_3$, -CN, $-NH_2$, -OH, $-NO_2$, $-COOH$, $-C(=O)NH_2$, halogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkylamino, C_{1-6} hydroxy-substituted alkyl, $(C_{1-6} \text{ alkyl})-C(=O)-$, $(C_{1-6} \text{ alkoxy})-C(=O)-$, $(C_{1-6} \text{ alkylamino})-C(=O)-$, cycloalkyl, heterocyclyl, aryl or heteroaryl.

2. The compound of claim 1, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, wherein each R^1 , R^2 , R^3 , R^4 , R^9 and R^{9a} is independently H, D, $-CD_3$, -CN, $-NH_2$, -OH, $-NO_2$, $-COOH$, $-C(=O)NH_2$, halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{1-4} alkylamino, C_{1-4} hydroxy-substituted alkyl, $(C_{1-4} \text{ alkyl})-C(=O)-$, $(C_{1-4} \text{ alkoxy})-C(=O)-$ or $(C_{1-4} \text{ alkylamino})-C(=O)-$.


3. The compound of claim 1, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, wherein each R^1 , R^2 , R^3 , R^4 , R^9 and R^{9a} is independently H, D, $-CD_3$, -CN, $-NH_2$, -OH, $-NO_2$, $-COOH$, $-C(=O)NH_2$, F, Cl, Br, I, methyl, ethyl, *n*-propyl, isopropyl, $-CF_3$, $-CH_2CF_3$, $-CF_2CF_3$, methoxy, ethoxy, *n*-propyloxy, isopropyloxy, $-NHCH_3$, $-N(CH_3)_2$ or $-CH_2OH$.

4. The compound having one of the following structures or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof,





and



5. A pharmaceutical composition comprising the compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, and optionally, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, excipient, adjuvant or a combination thereof.

6. A compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, for use in therapy.

7. Use of the compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 5 in the manufacture of a medicament for preventing, treating or lessening a disease related to one or more orexin receptors,

wherein the disease is a sleep disorder, depression, anxiety, a panic disorder, an obsessive-compulsive disorder, an affective disorder, depressive neurosis, anxiety neurosis, a mood disorder, a panic attack disorder, a behavior disorder, emotional disturbance, a post-traumatic stress disorder, sexual dysfunction, psychosis, schizophrenia, manic depression, mental disorders, dementia, drug dependence, addiction, a cognitive disorder, Alzheimer's disease, Parkinson's disease, a movement disorder, an eating disorder, headache, migraine, pain, a digestive system disease, epilepsy, inflammation, a cardiovascular disease, diabetes, a metabolic disease, an immunity-related disease, an endocrine-related disease or high blood pressure.

8. A pharmaceutical combination for use in treating or lessening a disease related to one or more orexin receptors, wherein the pharmaceutical combination comprises the compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, as a first active agent; and a medicament different from the compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, as the second active agent, wherein the medicament different from the compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, is for use in preventing, treating or lessening a disease related to one or more orexin receptors.

9. A kit for use in treating or lessening a disease related to one or more orexin receptors, wherein the kit comprises:

a first container, wherein the first container is provided with the compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof; and

optionally,

a second container, wherein the second container is provided with a medicament different from the compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, wherein the medicament different from the compound of any one of claims 1 to 4, or a stereoisomer, a tautomer, an *N*-oxide, a solvate or a pharmaceutically acceptable salt thereof, is for use in preventing, treating or lessening a disease related to one or more orexin receptors.